Celcuity Inc(CELC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CELC Celcuity Inc

已收盘 11-13 16:00:00 EST

64.37

+0.20

+0.31%

盘后64.37

+0.000.00%

19:30 EST

最高64.60	最低61.71	成交量64.65万
今开64.20	昨收64.17	日振幅4.50%
总市值31.62亿	流通市值19.25亿	总股本4,913万
成交额4,113万	换手率2.16%	流通股本2,991万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CELC","market":"US","secType":"STK","nameCN":"Celcuity Inc","latestPrice":64.37,"timestamp":1794603600000,"preClose":64.17,"halted":0,"volume":646496,"hourTrading":{"tag":"盘后","latestPrice":64.37,"preClose":64.37,"latestTime":"19:30 EST","volume":16617,"amount":1069651.64,"timestamp":1794616202123,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0031167212092878733,"floatShares":29911300,"shares":49126314,"eps":-4.720017,"marketStatus":"已收盘","change":0.2,"latestTime":"11-13 16:00:00 EST","open":64.2,"high":64.6,"low":61.71,"amount":41131036.859552,"amplitude":0.045037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.720017,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":64.17,"preHourTrading":{"tag":"盘前","latestPrice":65.21,"preClose":64.17,"latestTime":"09:28 EST","volume":219,"amount":13927.08381,"timestamp":1794580080058,"change":1.04,"changeRate":0.016207,"amplitude":0.032102},"postHourTrading":{"tag":"盘后","latestPrice":64.37,"preClose":64.37,"latestTime":"19:30 EST","volume":16617,"amount":1069651.64,"timestamp":1794616202123,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.738506,"impliedVol":0.8207,"impliedVolPercentile":0.8048},"requestUrl":"/m/hq/s/CELC","defaultTab":"news","newsList":[{"id":"2666942025","title":"王长俊现场推进重点项目建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2666942025","media":"盱眙发布","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666942025?lang=zh_cn&edition=full","pubTime":"2026-09-10 23:01","pubTimestamp":1789052460,"startTime":"0","endTime":"0","summary":"9月10日，县委书记王长俊现场推进重点项目建设。王长俊与企业负责人深入交流，详细了解项目规划、要素保障、施工筹备等推进情况，要求相关部门主动靠前服务、全程跟踪跟进，扎实做好审批办理、要素配套各项保障工作，对置换项目加快原地块建筑拆除、场地清理等工作，尽快实现净地交付，确保新项目10月份能够开工建设。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-10/doc-inirkiyn2622862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188384409","title":"Celcuity向FDA提交Revtorpyk™（Gedatolisib）补充新药申请，用于HR+/HER2-、PIK3CA突变局部晚期或转移性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1188384409","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188384409?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:31","pubTimestamp":1787747481,"startTime":"0","endTime":"0","summary":"Celcuity公司近日宣布，已正式向美国食品药品监督管理局提交了Revtorpyk的补充新药申请。此番申请针对的适应症为HR阳性、HER2阴性且携带PIK3CA突变的局部晚期或转移性乳腺癌患者群体。Revtorpyk作为一种潜在的治疗方案，其开发聚焦于特定的生物标志物定义人群——即在HR+/HER2-乳腺癌中检测到PIK3CA基因突变的患者。Celcuity此次提交的sNDA，若获FDA批准，将为这一特定患者亚群提供新的治疗选项。目前，FDA将对该补充新药申请进行审评，审评周期及最终决定时间尚待公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162791330","title":"获FDA新批准的Revtorpyk™（Gedatolisib）被纳入NCCN® HR+/HER2-局部晚期或转移性乳腺癌临床实践指南","url":"https://stock-news.laohu8.com/highlight/detail?id=1162791330","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162791330?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:31","pubTimestamp":1785414676,"startTime":"0","endTime":"0","summary":"近日，一款新获美国食品药品监督管理局（FDA）批准的药物——Revtorpyk™（通用名：Gedatolisib），已被正式纳入美国国家综合癌症网络®（NCCN®）的临床实践指南。该指南针对的是HR+/HER2-局部晚期或转移性乳腺癌患者。这一纳入标志着这款药物在肿瘤治疗领域的权威性认可迈出了关键一步。该消息由Celcuity Inc（CELC）公司对外披露。Revtorpyk™的加入，为特定类型的乳腺癌患者提供了全新的治疗选择与希望。指南的更新，将有助于临床医生在制定个体化治疗方案时，有更多循证依据可供参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184889176","title":"FDA批准Celcuity旗下Revtorpyk用于治疗无PIK3CA突变的HR+/HER2-晚期乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1184889176","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184889176?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:31","pubTimestamp":1785414675,"startTime":"0","endTime":"0","summary":"2026年7月14日，美国食品药品监督管理局（FDA）正式批准了Celcuity公司开发的药物Revtorpyk。该药物针对的是一种特定类型的晚期乳腺癌——激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER2-），且不携带PIK3CA基因突变。这一里程碑式的决定，为原本治疗选择有限的这部分患者群体，开辟了全新的治疗路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123499084","title":"异动解读｜Celcuity Inc盘中下跌22.15%，FDA批准核心药物后利好兑现引发深度抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1123499084","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123499084?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:33","pubTimestamp":1784122391,"startTime":"0","endTime":"0","summary":"7月15日，Celcuity Inc盘中下跌22.15%，报91.795美元/股，成交额4476.92万美元。消息面上，FDA正式批准公司核心药物REVTORPYK用于HR+/HER2-、PIK3CA野生型局部晚期或转移性乳腺癌，批准基于III期VIKTORIA-1试验数据。然而该股此前已因PDUFA审评日临近大幅走高，盘中一度涨超5%至109.21美元，正式获批后资金呈典型\"利好兑现\"式抛售并持续加深。此外，当前获批适应症仅限PIK3CA野生型患者，针对PIK3CA突变患者的补充申请尚需于第三季度提交，适应症范围窄于部分市场预期，加剧了卖压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179546739","title":"异动解读｜Celcuity Inc盘前下跌5.59%，FDA批准核心药物后市场兑现获利","url":"https://stock-news.laohu8.com/highlight/detail?id=1179546739","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179546739?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:59","pubTimestamp":1784113147,"startTime":"0","endTime":"0","summary":"7月15日，Celcuity Inc盘前下跌5.59%，报104.84美元/股，成交额9.01万美元。然而该股此前已因FDA审评日临近而大幅走高，盘中一度涨超5%，正式获批后资金呈典型\"利好兑现\"式抛售。此外，当前获批适应症仅限PIK3CA野生型患者，针对PIK3CA突变患者的补充申请尚需于第三季度提交，市场对适应症范围或存在预期差。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103001250","title":"异动解读｜Celcuity Inc夜盘下跌5.45%，FDA批准核心药物后市场兑现获利","url":"https://stock-news.laohu8.com/highlight/detail?id=1103001250","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103001250?lang=zh_cn&edition=full","pubTime":"2026-07-15 08:32","pubTimestamp":1784075567,"startTime":"0","endTime":"0","summary":"7月15日，Celcuity Inc夜盘下跌5.45%，报105.0美元/股，成交额4229.8美元。消息面上，FDA正式批准公司核心药物REVTORPYK用于HR+/HER2-、PIK3CA野生型局部晚期或转移性乳腺癌，批准基于III期VIKTORIA-1试验数据。然而该股此前已因FDA审评日临近大幅上涨，盘中一度涨超5%，正式获批后资金呈典型\"利好兑现\"式抛售。此外，当前获批适应症仅限PIK3CA野生型患者，针对PIK3CA突变患者的补充申请尚需于第三季度提交，市场对适应症范围或存在预期差。公司预计将于第三季度末启动商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124036184","title":"Celcuity公司宣布FDA批准Revtorpyk™ (gedatolisib) 用于治疗HR+/HER2-、PIK3CA野生型局部晚期或转移性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1124036184","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124036184?lang=zh_cn&edition=full","pubTime":"2026-07-15 04:54","pubTimestamp":1784062483,"startTime":"0","endTime":"0","summary":"Celcuity公司今日宣布，其新药Revtorpyk™ (gedatolisib) 已获得美国食品药品监督管理局（FDA）的批准。该药物获准用于治疗激素受体阳性、HER2阴性，且PIK3CA基因呈野生型的局部晚期或转移性乳腺癌患者。此项批准标志着针对这一特定乳腺癌亚型患者群体的一项重要治疗新选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124500511","title":"异动解读｜Celcuity Inc盘后下跌6.75%，报106.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124500511","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124500511?lang=zh_cn&edition=full","pubTime":"2026-07-15 04:43","pubTimestamp":1784061822,"startTime":"0","endTime":"0","summary":"7月15日，Celcuity Inc盘后下跌6.75%，报106.79美元/股，成交额332.07万美元。Celcuity Inc所在的生物科技行业中，个股中，艾伯维公司跌0.03%，Nextcure Inc.跌12.61%，渤健公司涨0.45%，吉利德科学涨0.17%，Revolution Medicines, Inc.跌0.52%。Celcuity Inc.是一家临床阶段的生物技术公司，专注于开发针对实体瘤的靶向疗法。其主要候选药物gedatolisib是一种PI3K/AKT/mTOR通路激酶抑制剂，目前正在进行针对HR+/HER2-晚期乳腺癌及其他适应症的3期临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123253973","title":"异动解读｜Celcuity盘中上涨5.22%，FDA关键审评日临近催化市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1123253973","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123253973?lang=zh_cn&edition=full","pubTime":"2026-07-15 03:15","pubTimestamp":1784056548,"startTime":"0","endTime":"0","summary":"7月15日，Celcuity盘中上涨5.22%，报109.21美元/股，成交额1.0亿美元。消息面上，FDA此前已受理Celcuity核心候选药物gedatolisib的新药申请并授予优先审评资格，PDUFA目标审评日期定于7月17日，距当前仅两日。市场对该药获批前景的乐观预期推动股价走强。此前公布的III期Viktoria-1试验数据显示，gedatolisib三联疗法将疾病进展或死亡风险降低50%，中位无进展生存期达11.1个月，远超对照组的5.6个月，客观缓解率分别为48.9%和35.7%，安全性整体良好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160136010","title":"异动解读｜Celcuity盘中下跌5.37%，FDA审评目标日期临近多空博弈加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1160136010","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160136010?lang=zh_cn&edition=full","pubTime":"2026-07-09 00:21","pubTimestamp":1783527689,"startTime":"0","endTime":"0","summary":"7月9日，Celcuity盘中下跌5.37%，报110.27美元/股，成交额5625.14万美元。该股前一交易日曾上涨5.02%。消息面上，公司核心候选药物gedatolisib的FDA处方药用户付费法案目标审评日期定于7月17日，距今不足10天。该药物已获FDA新药申请优先审评资格，用于HR+/HER2-/PIK3CA突变晚期乳腺癌治疗，III期Viktoria-1试验数据显示三联疗法将疾病进展或死亡风险降低50%，中位无进展生存期达11.1个月。临近重大二元催化事件，市场多空博弈加剧，股价出现回调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197009110","title":"异动解读｜Celcuity盘中上涨5.02%，核心药物FDA审评目标日期临近","url":"https://stock-news.laohu8.com/highlight/detail?id=1197009110","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197009110?lang=zh_cn&edition=full","pubTime":"2026-07-08 00:07","pubTimestamp":1783440465,"startTime":"0","endTime":"0","summary":"7月8日，Celcuity盘中上涨5.02%，报114.03美元/股，成交额5562.87万美元。消息面上，公司核心候选药物gedatolisib的FDA处方药用户付费法案目标审评日期定于7月17日，距今仅约一周。该药物此前已获FDA新药申请优先审评资格，用于HR+/HER2-/PIK3CA突变晚期乳腺癌治疗。III期Viktoria-1试验数据显示，gedatolisib三联疗法将疾病进展或死亡风险降低50%，中位无进展生存期达11.1个月，较对照组5.6个月近乎翻倍。市场对即将到来的FDA审批决定持乐观预期，推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187497120","title":"Celcuity Inc. 定价增发5亿美元、2032年到期的0.25%可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187497120","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187497120?lang=zh_cn&edition=full","pubTime":"2026-06-04 10:23","pubTimestamp":1780539808,"startTime":"0","endTime":"0","summary":"6月3日 - 生物技术公司 Celcuity Inc. 宣布，已为其增发的2032年到期、利率为0.250%的可转换优先票据完成定价。此次发行规模最终确定为5亿美元。\n该笔票据的发行规模较原计划有所扩大，凸显了市场对其融资条款的认可。可转换票据为投资者提供了未来将债务转换为公司股权的选择权，是成长型公司常见的融资工具之一。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187515046","title":"Celcuity Inc宣布公开发行2032年到期的可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187515046","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187515046?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:39","pubTimestamp":1780486794,"startTime":"0","endTime":"0","summary":"Celcuity Inc于6月3日宣布，将公开发行一批于2032年到期的可转换优先票据。此举旨在为公司运营及战略发展募集资金。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199488490","title":"异动解读｜Celcuity盘中下跌23.24%，III期VIKTORIA-1临床数据公布后股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1199488490","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199488490?lang=zh_cn&edition=full","pubTime":"2026-06-03 00:20","pubTimestamp":1780417249,"startTime":"0","endTime":"0","summary":"6月2日，Celcuity盘中下跌23.24%，报93.69美元/股，成交额3.2亿美元。消息面上，公司通过SEC文件公布了III期VIKTORIA-1试验PIK3CA突变队列结果：Gedatolisib三联疗法中位无进展生存期为11.1个月，对照组Alpelisib联合Fulvestrant为5.6个月；安全性方面不良事件多为低级别。FDA已授予其新药申请优先审评资格，PDUFA目标日期定为7月17日。尽管临床数据及监管进展积极，股价仍大幅回落，提示市场此前或已充分定价甚至对数据抱有更高预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169917585","title":"Celcuity公布III期VIKTORIA-1试验PIK3CA突变队列结果 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1169917585","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169917585?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:34","pubTimestamp":1780403640,"startTime":"0","endTime":"0","summary":"Celcuity公司近期通过提交给美国证券交易委员会的文件，公布了其关键III期VIKTORIA-1临床试验中针对PIK3CA突变患者队列的详细数据。安全性方面，gedatolisib相关治疗方案普遍耐受性良好，报告的大多数不良事件为低级别。美国食品药品监督管理局已授予Celcuity公司gedatolisib的新药申请优先审评资格，并设定了处方药用户付费法案目标日期为2026年7月17日。公司表示，若获得FDA批准，正按计划推进gedatolisib在2026年第三季度的商业化上市准备工作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107864078","title":"FDA授予Celcuity公司Gedatolisib新药申请优先审评资格；PDUFA目标日期定于2026年7月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=1107864078","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107864078?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:16","pubTimestamp":1780402573,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已授予Celcuity公司旗下药物Gedatolisib的新药申请（NDA）优先审评资格。根据提交至美国证券交易委员会（SEC）的文件，该申请的处方药使用者付费法案（PDUFA）目标日期设定为2026年7月17日。此举标志着该药物在监管审批流程中迈出了关键一步，有望加速其上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134324033","title":"Celcuity：Gedatolisib三联疗法对比Alpelisib联合Fulvestrant，中位无进展生存期达11.1个月 vs 5.6个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1134324033","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134324033?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:15","pubTimestamp":1780402521,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，Celcuity Inc 公布的数据显示，其Gedatolisib三联疗法在关键试验中取得了显著成果。\n该疗法展现出的中位无进展生存期达到11.1个月，而对照组使用Alpelisib联合Fulvestrant方案的中位无进展生存期仅为5.6个月。这一对比数据突显了Gedatolisib三联疗法的潜在优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179894923","title":"Celcuity公司：Gedatolisib治疗方案总体耐受性良好，不良事件多为低级别","url":"https://stock-news.laohu8.com/highlight/detail?id=1179894923","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179894923?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:15","pubTimestamp":1780402516,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，Celcuity Inc 在其临床研究中评估的Gedatolisib治疗方案展现出积极的耐受性特征。数据显示，该治疗方案总体上被患者良好耐受，所报告的大多数不良事件严重程度较低，属于低级别范畴。这一发现为后续的临床开发提供了支持性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113606237","title":"Celcuity公司将于2026年6月2日召开电话会议，讨论Gedatolisib方案针对HR+/HER-晚期乳腺癌的3期Viktoria-1临床试验中PIK3CA突变队列的结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1113606237","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113606237?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:30","pubTimestamp":1780317020,"startTime":"0","endTime":"0","summary":"Celcuity公司计划于2026年6月2日举行一场电话会议，专门探讨其关键候选药物Gedatolisib联合方案在HR+/HER-晚期乳腺癌患者中的最新临床数据。此次会议的核心议题，将聚焦于3期Viktoria-1临床试验中，针对携带PIK3CA基因突变的患者队列所获得的详细结果。该数据的公布，预计将为评估Gedatolisib在这一特定患者群体中的疗效与安全性提供关键洞见，并可能影响未来的治疗策略与监管路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celcuity.com","stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":0.0155},{"period":"3month","weight":-0.3025},{"period":"6month","weight":-0.5339},{"period":"1year","weight":-0.2464},{"period":"ytd","weight":-0.3566}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Celcuity Inc.于2011年在明尼苏达州注册成立为一家有限责任公司，并于2017年9月15日在特拉华州重新注册成立。该公司是一家临床阶段的生物技术公司，专注于开发针对实体瘤的靶向疗法。其主要候选药物gedatolisib是一种PI3K/AKT/mTOR通路激酶抑制剂，目前正在进行针对HR+/HER2-晚期乳腺癌及其他适应症的3期临床试验。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.002348},{"month":2,"riseRate":0.555556,"avgChangeRate":-0.027609},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.001524},{"month":4,"riseRate":0.666667,"avgChangeRate":0.07157},{"month":5,"riseRate":0.555556,"avgChangeRate":0.06966},{"month":6,"riseRate":0.666667,"avgChangeRate":0.064311},{"month":7,"riseRate":0.222222,"avgChangeRate":0.140265},{"month":8,"riseRate":0.666667,"avgChangeRate":0.018125},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.022693},{"month":10,"riseRate":0.5,"avgChangeRate":0.099994},{"month":11,"riseRate":0.4,"avgChangeRate":0.057123},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028056}],"exchange":"NASDAQ","name":"Celcuity Inc","nameEN":"Celcuity Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celcuity Inc(CELC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Celcuity Inc(CELC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Celcuity Inc,CELC,Celcuity Inc股票,Celcuity Inc股票老虎,Celcuity Inc股票老虎国际,Celcuity Inc行情,Celcuity Inc股票行情,Celcuity Inc股价,Celcuity Inc股市,Celcuity Inc股票价格,Celcuity Inc股票交易,Celcuity Inc股票购买,Celcuity Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celcuity Inc(CELC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Celcuity Inc(CELC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}